Tumor burden monitoring using cell-free tumor DNA could be limited by tumor heterogeneity in advanced breast cancer and should be evaluated together with radiographic imaging

BMC Cancer

Volumn 17, Issue 1, 2017, Pages

  García Saenz, José Angel ^a   Ayllón, Patricia ^a   Laig, Marion ^b   Acosta Eyzaguirre, Daniel ^c   García Esquinas, Marta ^a   Montes, Myriam ^a   Sanz, Julián ^a   Barquín, Miguel ^d   Moreno, Fernando ^a   Garcia Barberan, Vanesa ^a   Díaz Rubio, Eduardo ^a   Caldes, Trinidad ^a   Romero, Atocha ^a,d  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^b Thermo Fisher Scientific   (United States)

^c Facultad HM Hospitales de Ciencias de la Salud de la UCJC   (Spain)

^d HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

Breast cancer; CfDNA; DPCR; PIK3CA

Indexed keywords

CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CELL HETEROGENEITY; CENTRIFUGATION; CIRCULATING TUMOR CELL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORRELATION COEFFICIENT; DIAGNOSTIC IMAGING; DISEASE MARKER; DNA EXTRACTION; GENE FREQUENCY; HUMAN; IMAGE ANALYSIS; IMMUNOASSAY; MAJOR CLINICAL STUDY; PLASMID; POLYMERASE CHAIN REACTION; PROTEIN DENATURATION; RADIOGRAPHY; TUMOR VOLUME; BLOOD; BREAST TUMOR; CANCER STAGING; DNA MUTATIONAL ANALYSIS; FEMALE; GENETICS; MAMMOGRAPHY; MIDDLE AGED; MISSENSE MUTATION; PATHOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; BREAST NEOPLASMS; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; HUMANS; MAMMOGRAPHY; MIDDLE AGED; MUTATION, MISSENSE; NEOPLASM STAGING; PHOSPHATIDYLINOSITOL 3-KINASES; TUMOR BURDEN;

EID: 85016111436     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-017-3185-9     Document Type: Article

References (26)

1. Diamantis A, Magiorkinis E, Koutselini H. Fine-needle aspiration (FNA) biopsy: historical aspects. Folia Histochem Cytobio. 2003;47:191-7.
2. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366:883-92.
3. Romero A, Acosta-Eyzaguirre A, Sanz J, et al. Identification of E545k mutation in plasma from a PIK3CA wild-type metastatic breast cancer patient by array-based digital PCR. cfDNA a powerful tool for biomarker testing in advance disease. Transl Res. 2015;166:783-7.
4. Diehl F, Schmidt K, Choti MA, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008;14:985-90.
5. Wang JY, Hsieh JS, Chang MY, et al. Molecular detection of APC, K-ras, and p53 mutations in the serum of colorectal cancer patients as circulating biomarkers. World J Surg. 2004;28:721-6.
6. Dawson SJ, Tsui DW, Murtaza M, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med. 2013;368:1199-209.
7. Diaz Jr LA, Williams RT, Wu J, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature. 2012;486:537-40.
8. Sorensen BS, Wu L, Wei W, et al. Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinib. Cancer. 2014;120:3896-901.
9. Garcia-Murillas I, Schiavon G, Weigelt B, Ng C, Hrebien S, Cutts RJ, Cheang M, Osin P, Nerurkar A, Kozarewa I, Garrido JA, Dowsett M, Reis-Filho JS, Smith IE, Turner NC. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci Transl Med. 2015;7:302ra133.
10. Romero A, García-Sáenz JA, Fuentes-Ferrer M, et al. Correlation between response to neoadjuvant chemotherapy and survival in locally advanced breast cancer patients. Ann Oncol. 2013;24:655-61.
11. Ko ES, Han BK, Kim RB, et al. Analysis of factors that influence the accuracy of magnetic resonance imaging for predicting response after neoadjuvant chemotherapy in locally advanced breast cancer. Ann Surg Oncol. 2013;20:2562-8.
12. Suzuki C, Jacobsson H, Hatschek T, et al. Radiologic measurements of tumor response to treatment: practical approaches and limitations. Radiographics. 2008;28:329-44.
13. Charehbili A, Wasser MN, Smit VT, et al. Accuracy of MRI for treatment response assessment after taxane- and anthracycline-based neoadjuvant chemotherapy in HER2-negative breast cancer. Eur J Surg Oncol. 2014;40:1216-21.
14. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res. 2008;68:6084-91.
15. Banerji S, Cibulskis K, Rangel-Escareno C, et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature. 2012;486:405-9.
16. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumour. Nature. 2012;490:61-70.
17. Campbell IG, Russell SE, Choong DY, et al. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res. 2004;64:7678-81.
18. Higgins MJ, Jelovac D, Barnathan E, et al. Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood. Clin Cancer Res. 2012;18:3462-9.
19. Beaver JA, Jelovac D, Balukrishna S, et al. Detection of cancer DNA in plasma of patients with early-stage breast cancer. Clin Cancer Res. 2014;20:2643-50.
20. Rothé F, Laes JF, Lambrechts D, et al. Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer. Ann Oncol. 2014;25:1959-65.
21. Board RE, Wardley AM, Dixon JM, et al. Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer. Breast Cancer Res Treat. 2010;120:461-7.
22. Oshiro C, Kagara N, Naoi Y, et al. PIK3CA mutations in serum DNA are predictive of recurrence in primary breast cancer patients. Breast Cancer Res Treat. 2015;150:299-307.
23. Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl. 2014;6:224ra24.
24. Olsson E, Winter C, George A, et al. Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease. EMBO Mol Med. 2015;7:1034-47.
25. Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747-52.
26. Romero A, Prat A, García-Sáenz JA, et al. Assignment of tumor subtype by genomic testing and pathologic-based approximations: implications on patient's management and therapy selection. Clin Transl Oncol. 2014;16:386-94.